Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: FBR017
MIFTS: 61

Fibrosarcoma

Categories: Rare diseases, Bone diseases, Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Fibrosarcoma

About this section

MalaCards integrated aliases for Fibrosarcoma:

Name: Fibrosarcoma 12 76 53 59 29 55 44 15 73
Neoplasms, Fibrous Tissue 44 73
Fibrosarcoma of Soft Tissue 12
Fibrous Tissue Neoplasm 12
Fibrocytic Tumor 12

Characteristics:

Orphanet epidemiological data:

59
fibrosarcoma
Prevalence: <1/1000000 (Europe); Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Bone diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare bone diseases


External Ids:

Disease Ontology 12 DOID:3355
SNOMED-CT 68 443250000 53654007
Orphanet 59 ORPHA2030
MESH via Orphanet 45 D005354
UMLS via Orphanet 74 C0016057
ICD10 via Orphanet 34 C49.9
Sources

Summaries for Fibrosarcoma

About this section
Disease Ontology : 12 A connective tissue cancer that has material basis in fibrous connective tissue and characterized by the presence of immature proliferating fibroblasts or undifferentiated anaplastic spindle cells in a storiform pattern.

MalaCards based summary : Fibrosarcoma, also known as neoplasms, fibrous tissue, is related to pediatric fibrosarcoma and breast adenocarcinoma. An important gene associated with Fibrosarcoma is ETV6 (ETS Variant 6), and among its related pathways/superpathways are Integrin Pathway and Response to elevated platelet cytosolic Ca2+. The drugs Tamoxifen and Menthol have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and lung, and related phenotypes are shRNA abundance <= 50% and growth/size/body region

Wikipedia : 76 Fibrosarcoma (fibroblastic sarcoma) is a malignant mesenchymal tumour derived from fibrous connective... more...

Sources

Related Diseases for Fibrosarcoma

About this section

Diseases in the Fibrosarcoma family:

Adult Fibrosarcoma Congenital Fibrosarcoma

Diseases related to Fibrosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 221)
# Related Disease Score Top Affiliating Genes
1 pediatric fibrosarcoma 34.3 ETV6 NTRK3
2 breast adenocarcinoma 29.7 MMP9 PLAU TNF
3 cellular congenital mesoblastic nephroma 29.7 ETV6 NTRK3
4 rheumatoid arthritis 29.5 JUN MALAT1 MMP1 MMP9 TIMP1 TNF
5 aortic aneurysm, familial abdominal, 1 29.4 MMP1 MMP14 MMP2 MMP9 PLAU TIMP1
6 colorectal cancer 27.5 JUN MALAT1 MMP1 MMP14 MMP2 MMP9
7 breast cancer 27.0 JUN MALAT1 MMP1 MMP14 MMP2 MMP9
8 small bowel fibrosarcoma 12.1
9 liver fibrosarcoma 12.1
10 congenital fibrosarcoma 12.1
11 heart fibrosarcoma 12.1
12 breast fibrosarcoma 12.1
13 fibrosarcoma of bone 12.1
14 adult fibrosarcoma 12.0
15 central nervous system fibrosarcoma 12.0
16 kidney fibrosarcoma 11.9
17 conventional fibrosarcoma 11.9
18 dermatofibrosarcoma protuberans 11.4
19 desmoid tumor 11.2
20 infantile myofibromatosis 11.2
21 diaphyseal medullary stenosis with malignant fibrous histiocytoma 11.2
22 inflammatory myofibroblastic tumor 11.2
23 extracranial arteriovenous malformation 11.1 MMP2 MMP9
24 adult mesoblastic nephroma 11.1 ETV6 NTRK3
25 focal myositis 11.1 MMP2 MMP9
26 amaurosis fugax 11.0 MMP9 SERPINE1
27 lentigo maligna melanoma 11.0 MMP2 MMP9
28 conjunctival nevus 10.9 MMP2 MMP9 TIMP1
29 spastic entropion 10.9 MMP1 MMP2 MMP9
30 lung giant cell carcinoma 10.9 MMP2 MMP9 TIMP1
31 internal hemorrhoid 10.9 MMP1 MMP2 MMP9
32 chronic venous leg ulcers 10.9 MMP9 TIMP1
33 multicentric osteolysis, nodulosis, and arthropathy 10.9 MMP14 MMP2
34 odontogenic myxoma 10.9 MMP1 MMP2 MMP9
35 villous adenocarcinoma 10.9 MMP2 MMP9
36 diabetic foot ulcers 10.9 MMP9 TIMP1
37 chromosome 17q11.2 deletion syndrome 10.9
38 hypertensive heart disease 10.9 MMP1 MMP2 MMP9
39 winchester syndrome 10.9 MMP14 MMP2
40 aortic aneurysm, familial thoracic 1 10.9 MMP1 MMP2 MMP9
41 aortic disease 10.9 MMP2 MMP9 TIMP1
42 chronic actinic dermatitis 10.9 MMP1 MMP9
43 carotid artery disease 10.8 MMP1 MMP9 TIMP1
44 transverse myelitis 10.8 MMP2 MMP9 TNF
45 autoimmune inner ear disease 10.8 MMP9 TIMP1 TNF
46 psammomatous meningioma 10.8 MMP2 MMP9
47 gingival fibromatosis 10.8 MMP1 MMP2 TIMP1
48 acute transverse myelitis 10.8 MMP2 MMP9
49 appendicitis 10.8 MMP9 TIMP1 TNF
50 lymphangioleiomyomatosis 10.8 MMP1 MMP14 MMP2

Graphical network of the top 20 diseases related to Fibrosarcoma:



Diseases related to Fibrosarcoma
Sources

Symptoms & Phenotypes for Fibrosarcoma

About this section

GenomeRNAi Phenotypes related to Fibrosarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.36 ETV6 JUN MAF MAFB MAFF MAFG

MGI Mouse Phenotypes related to Fibrosarcoma:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.4 MMP14 MAFG MMP2 MAFK MMP9 SERPINE1
2 immune system MP:0005387 10.38 MAFG MMP2 MAFK MMP1 MMP14 MMP9
3 cardiovascular system MP:0005385 10.37 MMP14 MMP2 MMP9 SERPINE1 NTRK3 TIMP1
4 homeostasis/metabolism MP:0005376 10.37 MAFB MMP14 MMP2 MMP1 MMP9 SERPINE1
5 behavior/neurological MP:0005386 10.35 MAFB MMP14 MAFG MAFK PLAU MMP9
6 hematopoietic system MP:0005397 10.32 MMP14 MAFG MMP2 MAFK MMP9 SERPINE1
7 mortality/aging MP:0010768 10.31 MAFB MMP14 MAFG MMP2 MAFK MMP9
8 endocrine/exocrine gland MP:0005379 10.19 MAFB MMP14 PLAU TIMP1 JAK1 MAFA
9 nervous system MP:0003631 10.15 MAFB MMP14 MAFG MAFK MMP2 PLAU
10 integument MP:0010771 10.11 MMP14 PLAU MMP9 SERPINE1 JAK1 TNF
11 craniofacial MP:0005382 10.09 MAFB MMP14 MMP2 PLAU JAK1 TNF
12 normal MP:0002873 10.02 MAFB MMP14 MAFF MMP2 NTRK3 MAFA
13 neoplasm MP:0002006 10.01 MMP2 MMP1 MMP9 SERPINE1 TIMP1 PLAU
14 respiratory system MP:0005388 9.9 MMP9 MMP2 MMP14 SERPINE1 NTRK3 TIMP1
15 renal/urinary system MP:0005367 9.8 MAFB MMP14 MMP9 SERPINE1 MAF JAK1
16 skeleton MP:0005390 9.61 MAFB MMP14 MMP2 PLAU MMP9 TIMP1
17 vision/eye MP:0005391 9.23 MMP14 MMP2 PLAU MMP9 NTRK3 TNF
Sources

Drugs & Therapeutics for Fibrosarcoma

About this section

Drugs for Fibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 216)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamoxifen Approved Phase 4,Phase 2,Phase 1 10540-29-1 2733526
2
Menthol Approved Phase 4 2216-51-5 16666
3 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 1,Not Applicable
4 Bone Density Conservation Agents Phase 4,Phase 2,Phase 1
5 Estrogen Receptor Modulators Phase 4,Phase 2,Phase 1
6 Estrogens Phase 4,Phase 2,Phase 1,Early Phase 1
7 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
8 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
10 Selective Estrogen Receptor Modulators Phase 4,Phase 2,Phase 1
11 Analgesics Phase 4,Phase 2,Phase 1
12 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1
13 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 1
15 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
16 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Dermatologic Agents Phase 4,Phase 3,Phase 2
18 Efamol Phase 4
19 Estrogen Antagonists Phase 4,Phase 2,Phase 1
20 Hypolipidemic Agents Phase 4
21 Lipid Regulating Agents Phase 4
22 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1,Not Applicable
23 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable
24 Anesthetics, Local Phase 4,Phase 3,Phase 2
25 Evening Primrose Nutraceutical Phase 4
26
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
27
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
28
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
29
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
30
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
31
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
32
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
33
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 2019 457193
34
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
35
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
36
Petrolatum Approved, Investigational Phase 2, Phase 3 8009-03-8
37
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
38
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
39
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
40
Sorafenib Approved, Investigational Phase 3,Phase 2 284461-73-0 216239 406563
41
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
42
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
43
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
44
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
45
Cyproheptadine Approved Phase 3 129-03-3 2913
46
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
47
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 11103-57-4, 68-26-8 445354
48
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
49
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2 59-67-6 938
50
Nicotinamide Approved, Investigational, Nutraceutical Phase 3,Phase 2 98-92-0 936

Interventional clinical trials:

(show top 50) (show all 252)
# Name Status NCT ID Phase Drugs
1 Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer Completed NCT00999921 Phase 4 Tamoxifen;Evening Primrose Oil
2 Retreatment of Recurrent Dupuytren's Contractures Completed NCT01498640 Phase 4
3 MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex Completed NCT01450397 Phase 4
4 Efficacy and Safety of Xiaflex Injection for Treatment of Dupuytren's Contracture of the Thumb Completed NCT01265420 Phase 4
5 Prospective Trial Comparing the Performance Profiles of Two Non-Cross-Linked Porcine Dermal Matrices in Abdominal Wall Reconstruction Recruiting NCT02228889 Phase 4
6 Trial Comparing Treatment Strategies in Dupuytren's Contracture Recruiting NCT03192020 Phase 4 Collagenase Clostridium Histolyticum 2.9 MG/ML [Xiaflex]
7 Collagenase Injection vs Percutaneous Needle Aponeurotomy for Dupuytren's Disease Recruiting NCT03000114 Phase 4 XIAFLEX
8 Prospective Randomized Trial Between Needle Fasciotomy and Xiapex for Dupuytrens Contracture Recruiting NCT02476461 Phase 4 xiapex
9 Dupuytren´s Disease Study. Primary Disease, MCP Joint, Xiapex, PNF Active, not recruiting NCT02647619 Phase 4 Xiapex
10 Fasciectomy vs Collagenase Injection in Recurrent Dupuytren Disease Enrolling by invitation NCT03406338 Phase 4 Collagenase Clostridium Histolyticum
11 Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture Terminated NCT01226121 Phase 4
12 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
13 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
14 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
15 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
16 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
17 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
18 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
19 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
20 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
21 Non-US Study of AA4500 (XIAFLEXâ„¢, Proposed Name) in the Treatment of Advanced Dupuytren's Disease Completed NCT00533273 Phase 3
22 Safety and Efficacy Study of AA4500 (XIAFLEXâ„¢, Proposed Name) in the Treatment of Advanced Dupuytren's Disease Completed NCT00528840 Phase 3
23 AA4500 (XIAFLEXâ„¢, Proposed Name) in the Treatment of Advanced Dupuytren's Disease Completed NCT00528424 Phase 3
24 Collagenase in the Treatment of Dupuytrens Disease Completed NCT00260429 Phase 3
25 Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures Completed NCT01674634 Phase 3
26 Collagenase Option for Reduction of Dupuytren's Contracture in Japan Completed NCT01588353 Phase 3 Collagenase Clostridium Histolyticum
27 Administration of Two Injections for Multiple Dupuytren's Contractures Completed NCT01407068 Phase 3
28 Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex) Completed NCT01229436 Phase 3 Xiapex
29 Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound Healing Completed NCT00931567 Phase 2, Phase 3
30 Effects of Steroid Injection With Percutaneous Needle Aponeurotomy in Dupuytren's Contracture Completed NCT00565019 Phase 3 Triamcinolone Acetonide
31 AA4500 (XIAFLEXâ„¢, Proposed Name) in the Treatment of Dupuytren's Contracture Completed NCT00528606 Phase 3
32 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
33 Phase III Randomized Study of Collagenase in Patients With Residual Stage Dupuytren's Disease Completed NCT00014742 Phase 3 collagenase
34 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
35 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
36 Ledderhose Disease: Radiotherapy or Not? Recruiting NCT03507010 Phase 3
37 Evaluation of Xiaflex: Trial of Effectivenss iN Dupuytren's Recruiting NCT02725528 Phase 3 collagenase injection
38 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
39 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
40 Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Active, not recruiting NCT02066181 Phase 3 Sorafenib Tosylate
41 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
42 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
43 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
44 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
45 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
46 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
47 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
48 MR Guided Focused Ultrasound Surgery in the Treatment of Breast Fibroadenomas Terminated NCT00147108 Phase 3
49 Collagenase and Needle Aponeurotomy: Single Modality Versus Combination Treatment for Dupuytren's Disease Withdrawn NCT01776892 Phase 3 Collegenase injection
50 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3

Search NIH Clinical Center for Fibrosarcoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: fibrosarcoma

Sources

Genetic Tests for Fibrosarcoma

About this section

Genetic tests related to Fibrosarcoma:

# Genetic test Affiliating Genes
1 Fibrosarcoma 29
Sources

Anatomical Context for Fibrosarcoma

About this section

MalaCards organs/tissues related to Fibrosarcoma:

41
Bone, Breast, Lung, Bone Marrow, T Cells, Liver, Colon
Sources

Publications for Fibrosarcoma

About this section

Articles related to Fibrosarcoma:

(show top 50) (show all 958)
# Title Authors Year
1
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. ( 29553955 )
2018
2
Genomics of a pediatric ovarian fibrosarcoma. Association with the DICER1 syndrome. ( 29459759 )
2018
3
Recurrent BCOR internal tandem duplication and BCOR or BCL6 expression distinguish primitive myxoid mesenchymal tumor of infancy from congenital infantile fibrosarcoma. ( 29430000 )
2018
4
Solubilization of a Poorly Soluble B-Raf (Rapidly Accelerated Fibrosarcoma) Inhibitor: From Theory to Application. ( 28989016 )
2018
5
Oxygen microbubbles improve radiotherapy tumor control in a rat fibrosarcoma model - A preliminary study. ( 29630640 )
2018
6
Primary Renal Hybrid Low-grade Fibromyxoid Sarcoma-Sclerosing Epithelioid Fibrosarcoma: An Unusual Pediatric Case With EWSR1-CREB3L1 Fusion. ( 29426275 )
2018
7
CT and MRI Findings of Soft Tissue Adult Fibrosarcoma in Extremities. ( 29693010 )
2018
8
Caffeine induces metformin anticancer effect on fibrosarcoma in hamsters. ( 29762853 )
2018
9
Outcomes following surgical excision or surgical excision combined with adjunctive, hypofractionated radiotherapy in dogs with oral squamous cell carcinoma or fibrosarcoma. ( 29911943 )
2018
10
Juvenile Bronchopulmonary Fibrosarcoma. ( 29944599 )
2018
11
Intensive fibrosarcoma-binding capability of the reconstituted analog and its antitumor activity. ( 29250984 )
2018
12
Spinal Sclerosing Epithelioid Fibrosarcoma at the Cervicothoracic Junction. ( 29574223 )
2018
13
Development of Orally Applicable, Combinatorial Drug-Loaded Nanoparticles for the Treatment of Fibrosarcoma. ( 29339136 )
2018
14
Disodium Cromolyn and Anti-podoplanin Antibodies Strongly Inhibit Growth of BHK 21/C13-derived Fibrosarcoma in a Chick Embryo Chorioallantoic Membrane Model. ( 29936460 )
2018
15
Successful management of congenital/infantile fibrosarcoma presenting as large, non-healing buttock ulceration. ( 29630153 )
2018
16
Primary tumor or metastasis? Extremely rare fibrosarcoma of the left atrial appendage. ( 29784427 )
2018
17
Sclerosing Epithelioid Fibrosarcoma of the Coccyx: A Case Report and Review of Literature. ( 29872588 )
2018
18
Rhodocetin-I+I^ selectively breaks the endothelial barrier of the tumor vasculature in HT1080 fibrosarcoma and A431 epidermoid carcinoma tumor models. ( 29854288 )
2018
19
Recurrent fibrosarcoma of maxillary sinus involving the cranial base: A rare case. ( 29970723 )
2018
20
Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics. ( 29863809 )
2018
21
Peroxiredoxin 1 (PRDX1) Suppresses Progressions and Metastasis of Osteosarcoma and Fibrosarcoma of Bone. ( 29908016 )
2018
22
Fibrosarcoma arising in the paranasal sinus: a clinicopathological and radiological analysis. ( 29658783 )
2018
23
Unusual Presentation of Fibrosarcoma in a Child. ( 29615178 )
2018
24
ADAMTS-1 disrupts HGF/c-MET signaling and HGF-stimulated cellular processes in fibrosarcoma. ( 29355494 )
2018
25
The effects of gene therapy with granulocyte-macrophage colony-stimulating factor in the regression of tumor masses in fibrosarcoma mouse model. ( 28643761 )
2017
26
Fibrosarcoma of the eyelid in two sibling Czech wolfdogs. ( 28616389 )
2017
27
Harnessing the heart's resistance to malignant tumors: cardiac-derived extracellular vesicles decrease fibrosarcoma growth and leukemia-related mortality in rodents. ( 29245929 )
2017
28
Congenital infantile fibrosarcoma mimicking a cutaneous vascular lesion: a case report and review of the literature. ( 27910123 )
2017
29
Metastatic Sclerosing Epithelioid Fibrosarcoma in Bone Marrow. ( 28697683 )
2017
30
Photodynamic therapy in fibrosarcoma BALB/c animal model: Observation of the rebound effect. ( 29155337 )
2017
31
Induction of antitumor response to fibrosarcoma by Newcastle disease virus-infected tumor vaccine. ( 28864944 )
2017
32
A meningeal fibrosarcoma on the same site of osteodural decompression: a pure coincidence? ( 28643506 )
2017
33
Congenital Infantile Fibrosarcoma in the Premature Infant. ( 29099410 )
2017
34
Korean Sa-Ahm Acupuncture for Treating Canine Oral Fibrosarcoma. ( 28712481 )
2017
35
Primary fibrosarcoma of the urinary bladder in a cat: follow-up after incomplete surgical excision. ( 28680699 )
2017
36
Congenital Infantile Fibrosarcoma Causing Intestinal Perforation in a Newborn. ( 28690909 )
2017
37
MicroRNA-29 Family Suppresses the Invasion of HT1080 Human Fibrosarcoma Cells by Regulating Matrix Metalloproteinase 2 Expression. ( 28584796 )
2017
38
Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma. ( 28877062 )
2017
39
Sclerosing Epithelioid Fibrosarcoma of the Jaw: Late Recurrence from a Low Grade Fibromyxoid Sarcoma. ( 29274042 )
2017
40
A delayed presentation of ameloblastic fibrosarcoma in an African patient. ( 28765185 )
2017
41
IGF-I regulates HT1080 fibrosarcoma cell migration through a syndecan-2/Erk/ezrin signaling axis. ( 28962916 )
2017
42
Recurrent BCOR internal tandem duplication and BCOR or BCL6 expression distinguish primitive myxoid mesenchymal tumor of infancy from congenital infantile fibrosarcoma. ( 28256570 )
2017
43
Enhanced cellular functions through induction of LPA2 by cisplatin in fibrosarcoma HT1080 cells. ( 28205098 )
2017
44
Effect of TERT on the growth of fibrosarcoma via caspase-3, survivin and PKB. ( 28789428 )
2017
45
In-depth genetic analysis of sclerosing epithelioid fibrosarcoma reveals recurrent genomic alterations and potential treatment targets. ( 28939748 )
2017
46
Primary sclerosing epithelioid fibrosarcoma of the pleura. ( 29340499 )
2017
47
Primary Central Nervous System Fibrosarcoma. ( 28936084 )
2017
48
Destructive Fibrosarcoma of the Maxillary Sinus. ( 29283942 )
2017
49
LipodoxAr (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus CaelyxAr (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models. ( 28587612 )
2017
50
Evaluation of fluorescence-guided surgery agents in a murine model of soft tissue fibrosarcoma. ( 29284070 )
2017
Sources

Variations for Fibrosarcoma

About this section

Cosmic variations for Fibrosarcoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM27895 GNAS bone,femur,osteosarcoma,fibroblastic c.602G>A p.R201H 20:58909366-58909366 4
Sources

Expression for Fibrosarcoma

About this section
Search GEO for disease gene expression data for Fibrosarcoma.
Sources

Pathways for Fibrosarcoma

About this section

Pathways related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Integrin Pathway 64
Show member pathways
 13.37 JAK1 JUN MMP1 MMP2 MMP9 PLAU
2
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 13.28 JAK1 MAFF MAFG MAFK MMP1 PLAU
3
Pathways in cancer 37
12.79 JAK1 JUN MMP1 MMP2 MMP9
4
Degradation of the extracellular matrix 66
Show member pathways
 12.66 MMP1 MMP14 MMP2 MMP9 SERPINE1 TIMP1
5
Th17 cell differentiation 37
Show member pathways
 12.41 JAK1 JUN MAF TNF
6
IL-17 Family Signaling Pathways 65
Show member pathways
 12.29 JAK1 JUN MMP1 MMP9 TNF
7
Proteoglycans in cancer 37
12.26 MMP2 MMP9 PLAU TNF
8
Transcriptional misregulation in cancer 37
12.22 ETV6 MAF MMP9 PLAU
9
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.16 JAK1 JUN MMP1 SERPINE1 TIMP1
10
Colorectal Cancer Metastasis 64
12.13 JAK1 MMP1 MMP14 MMP2 MMP9 TNF
11
Fluid shear stress and atherosclerosis 37
12.07 JUN MMP2 MMP9 TNF
12
Adhesion 4
12 MMP14 MMP2 MMP9 SERPINE1
13
TNF signaling pathway 37
11.93 JUN MMP14 MMP9 TNF
14
Senescence and Autophagy in Cancer 1
11.92 JUN MMP14 PLAU SERPINE1
15
AGE-RAGE signaling pathway in diabetic complications 37
11.87 JUN MMP2 SERPINE1 TNF
16
Interleukin-4 and 13 signaling 66
11.86 JAK1 MMP1 MMP2 MMP9 TIMP1 TNF
17
Angiogenesis (CST) 4
11.82 MMP2 MMP9 TIMP1 TIMP2
18
Rheumatoid arthritis 37
11.81 JUN MMP1 TNF
19
IL6-mediated signaling events 1
Show member pathways
 11.78 JAK1 JUN TIMP1
20
Regulation of Wnt-mediated beta catenin signaling and target gene transcription 1
11.74 JUN MMP2 MMP9
21
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.72 JUN MAF TNF
22
Bladder cancer 37 1
11.7 MMP1 MMP2 MMP9
23
Matrix Metalloproteinases 1
Show member pathways
 11.7 MMP1 MMP14 MMP2 MMP9 TIMP1 TIMP2
24
AGE/RAGE pathway 1
11.66 JUN MMP14 MMP2 MMP9
25
LPA receptor mediated events 1
11.65 JUN MMP2 MMP9
26
Lung fibrosis 1
11.6 MMP2 MMP9 PLAU TIMP1 TNF
27
TGF-beta Receptor Signaling (WikiPathways) 1
11.59 JAK1 JUN SERPINE1 TNF
28
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.57 JUN MMP1 MMP2 MMP9 TNF
29
ATF-2 transcription factor network 1
11.56 JUN MMP2 PLAU
30
Hepatitis C and Hepatocellular Carcinoma 1
11.53 JAK1 JUN MMP1
31
Photodynamic therapy-induced AP-1 survival signaling. 1
11.52 JUN MMP2 TNF
32
Interleukin-10 signaling 66
11.5 JAK1 TIMP1 TNF
33
FGF signaling pathway 1
11.48 JUN MMP9 PLAU
34
amb2 Integrin signaling 1
11.48 MMP2 MMP9 PLAU TNF
35
Osteopontin-mediated events 1
Show member pathways
 11.43 JUN MMP2 MMP9 PLAU
36
Cell adhesion_Cell-matrix glycoconjugates 22
11.38 MMP1 MMP9 TIMP2
37
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.19 JUN MMP1 MMP2 MMP9 PLAU
38
IL1 and megakaryocytes in obesity 1
11.16 MMP9 TIMP1 TIMP2
39
Tacrolimus/Cyclosporine Pathway, Pharmacodynamics 61
11.14 JUN MAF MAFA MAFB MAFF MAFG
40
Cell adhesion_ECM remodeling 22
11.01 MMP1 MMP14 MMP2 MMP9 PLAU SERPINE1
41
Immune response_Oncostatin M signaling via JAK-Stat in human cells 22
11 JAK1 MMP1 TIMP1
42
Dissolution of Fibrin Clot 66
10.8 PLAU SERPINE1
Sources

GO Terms for Fibrosarcoma

About this section

Cellular components related to Fibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 MMP14 MMP2 MMP9 PLAU SERPINE1 TIMP1
2 extracellular matrix GO:0031012 9.17 MMP1 MMP14 MMP2 MMP9 SERPINE1 TIMP1

Biological processes related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 transcription by RNA polymerase II GO:0006366 9.91 ETV6 JUN MAF MAFA MAFB MAFF
2 angiogenesis GO:0001525 9.87 JUN MMP14 MMP2 SERPINE1
3 positive regulation of cell migration GO:0030335 9.86 MMP14 MMP9 NTRK3 PLAU
4 blood coagulation GO:0007596 9.84 MAFF MAFG MAFK PLAU
5 regulation of cell proliferation GO:0042127 9.83 JAK1 JUN MAFG PLAU TNF
6 positive regulation of transcription by RNA polymerase II GO:0045944 9.81 ETV6 JUN MAF MAFA MAFB MAFF
7 circadian rhythm GO:0007623 9.76 JUN NTRK3 SERPINE1
8 ephrin receptor signaling pathway GO:0048013 9.75 MMP2 MMP9 NTRK3
9 cytokine-mediated signaling pathway GO:0019221 9.73 JAK1 MMP1 MMP2 MMP9 TIMP1 TNF
10 response to organic substance GO:0010033 9.71 JUN TIMP1 TIMP2 TNF
11 response to cytokine GO:0034097 9.7 JUN TIMP1 TIMP2
12 response to hormone GO:0009725 9.69 MMP14 TIMP1 TIMP2
13 endodermal cell differentiation GO:0035987 9.63 MMP14 MMP2 MMP9
14 collagen catabolic process GO:0030574 9.62 MMP1 MMP14 MMP2 MMP9
15 lens fiber cell differentiation GO:0070306 9.59 MAF NTRK3
16 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.55 TIMP1 TIMP2
17 negative regulation of metallopeptidase activity GO:1905049 9.49 TIMP1 TIMP2
18 regulation of epidermal cell differentiation GO:0045604 9.48 MAFF MAFG
19 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.26 JUN MMP2 MMP9 TNF
20 extracellular matrix disassembly GO:0022617 9.1 MMP1 MMP14 MMP2 MMP9 TIMP1 TIMP2

Molecular functions related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.93 MMP1 MMP14 MMP2 MMP9 TIMP1 TIMP2
2 peptidase activity GO:0008233 9.88 MMP1 MMP14 MMP2 MMP9 PLAU
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.8 ETV6 JUN MAFA MAFB MAFG
4 DNA binding transcription factor activity GO:0003700 9.76 ETV6 JUN MAF MAFA MAFB MAFF
5 transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding GO:0001077 9.72 ETV6 JUN MAFA MAFB MAFG
6 metallopeptidase activity GO:0008237 9.67 MMP1 MMP14 MMP2 MMP9
7 metalloendopeptidase activity GO:0004222 9.56 MMP1 MMP14 MMP2 MMP9
8 metalloendopeptidase inhibitor activity GO:0008191 9.51 TIMP1 TIMP2
9 serine-type endopeptidase activity GO:0004252 9.35 MMP1 MMP14 MMP2 MMP9 PLAU
10 protease binding GO:0002020 8.92 SERPINE1 TIMP1 TIMP2 TNF
11 protein binding GO:0005515 10.42 ETV6 JAK1 JUN MAF MAFB MAFF
12 RNA polymerase II transcription factor activity, sequence-specific DNA binding GO:0000981 10.03 ETV6 JUN MAF MAFA MAFB MAFF
Sources

Sources for Fibrosarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....